Navigation Links
Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
Date:2/2/2010

mber of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.

(1)  The FDA is currently evaluating a proposed brand name, Laviv™.

SOURCE Fibrocell Science, Inc.

RELATED LINKS
http://www.fibrocellscience.com

'/>"/>

SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
2. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
3. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
4. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
5. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
6. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
7. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
8. For creating new field of science, Texas chemist wins international prize
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
11. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... Tengion, Inc. (NASDAQ: TNGN ), a leader ... the Company,s Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) ... North America Annual Conference being held December 11-14, in ... further supported by various cellular and molecular studies demonstrating ...
... Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation ... of a Phase 2 study of quizartinib (formerly AC220) ... 53rd Annual Meeting of the American Society of Hematology ... from two additional posters: one evaluating the pharmacodynamic effects ...
... 13, 2011 Tarsa Therapeutics today confirmed that it ... to the Food and Drug Administration (FDA) in the ... recombinant salmon calcitonin tablet for the treatment of postmenopausal ... that verified the results from Tarsa,s Phase III ORACAL ...
Cached Biology Technology:Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 2Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 3Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3
(Date:7/14/2014)... East Anglia have shown how the main psychoactive ingredient ... , Research published today reveals the existence of ... drug,s success in shrinking tumours. , It is ... equivalent with anti-cancer properties. , The research ... The team used samples of human breast cancer cells ...
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... ON Physical activity is being increasingly recognized as ... Mammen,s review published in the October issue of the ... the connection one step further, finding that moderate exercise ... term. This is the first longitudinal review to ...
... Oct. 28, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2013.  ... decrease of 15% compared to $5.3 million in the same quarter ... was $1.2 million, or $0.05 per diluted share, which compares to ...
... age of agriculture that began in the 1960s, potassium chloride ... widely used as a major fertilizer in the Corn Belt ... recognized for their fundamental importance to soil fertility. Three University ... approach to potassium management that has been in place for ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2013 Financial Results 2Aware, Inc. Reports Third Quarter 2013 Financial Results 3Aware, Inc. Reports Third Quarter 2013 Financial Results 4Aware, Inc. Reports Third Quarter 2013 Financial Results 5Study challenges soil testing for potassium and the fertilizer value of potassium chloride 2Study challenges soil testing for potassium and the fertilizer value of potassium chloride 3Study challenges soil testing for potassium and the fertilizer value of potassium chloride 4
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Phosphatase ( l-PPase) is ... with activity towards phosphorylated ... residues. It is the ... the ORF221 open reading ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... refrigerated cold traps offers a choice of ... solvents or high volatility solvents. Ideal to ... evaporators. Also used for maintaining vapor-free gas ... in electron microscopes. Can be used as ...
Biology Products: